Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Phathom Pharmaceuticals (PHAT) Shares Issued (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Shares Issued for 5 consecutive years, with $591000.0 as the latest value for Q1 2026.

  • For Q1 2026, Shares Issued changed N/A year-over-year to $591000.0; the TTM value through Mar 2026 reached $544.3 million, down 63.91%, while the annual FY2025 figure was $1.6 million, 2.44% up from the prior year.
  • Shares Issued hit $591000.0 in Q1 2026 for Phathom Pharmaceuticals, down from $543.3 million in the prior quarter.
  • Across five years, Shares Issued topped out at $543.3 million in Q3 2024 and bottomed at $80000.0 in Q2 2025.
  • Average Shares Issued over 5 years is $183.9 million, with a median of $38.7 million recorded in 2023.
  • Year-over-year, Shares Issued soared 1303.88% in 2024 and then tumbled 99.98% in 2025.
  • Phathom Pharmaceuticals' Shares Issued stood at $24.6 million in 2022, then surged by 57.32% to $38.7 million in 2023, then skyrocketed by 1303.88% to $543.3 million in 2024, then changed by 0.0% to $543.3 million in 2025, then crashed by 99.89% to $591000.0 in 2026.
  • According to Business Quant data, Shares Issued over the past three periods came in at $591000.0, $543.3 million, and $293000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.